Amylin based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management, type 2 diabetes and more! Eloralintide, a selective amylin receptor agonist Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta Analysis Journal of Clinical Question Recent achievements and future directions of anti obesity medications Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications Obesity Week 2025 Medications Eli Lilly's Eloralintide Phase 2 Trial shows up to 20% Weight Loss with Promising Tolerability in Adults with Obesity Pharmacally